• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma
In this study, we treated ten patients with newly diagnosed MG with apixaban, 2.5  mg twice daily beginning 2–21 days after craniotomy and continuing for up to 6 months. Unacceptable toxicity was defined by ≥ grade 2 CNS or non-CNS hemorrhage, a thromboembolic event (i.e. stroke) or cardiovascular event requiring anticoagulation or anti-platelet therapy. There were no unacc eptable toxicities to report and no treatment-related adverse events. None of the patients on the study were diagnosed with a VTE while receiving apixaban. We conclude that apixaban can be given safely to patients with primary MG shortly after cra...
Source: Journal of Thrombosis and Thrombolysis - August 4, 2021 Category: Hematology Source Type: research